In conclusion, although AG-205 may seem attractive for the development of new therapeutic strategies due to its various effects, in particular against cancer progression, it should no longer be considered as a PGRMC1 inhibitor and its precise mechanisms of action and potential detrimental side-effects in medical use should be carefully investigated and documented in the future. The gene discussed is PGRMC1; the disease is cancer.